Function of Appican and Sulfation Pattern in AD Brains
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
A2000024
Summary
The amyloid precursor protein (APP) is produced in different forms (called isoforms), and one of these isoforms has been found by Dr. Shioi to be the core protein of a complex type of protein called a chondroitin sulfate proteoglycan (a protein that contains sulfur and sugar molecules). Dr. Shioi calls this APP-containing protein “appican.” Appican is found in brain tissue and is produced by a type of brain cell (called an astrocyte) in cell culture, but non-neuronal cell lines produce little or no appican. Recent evidence suggests that chondroitin sulfate proteoglycans are involved in neuronal growth and development. Dr. Shioi is examining the possible role of appican in normal brain function and whether this role is changed in Alzheimer’s disease (AD). The results of these experiments could identify a new role for the APP protein in AD.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Regulatory mechanisms underlying endosomal targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory mechanisms underlying endosomal targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD